| 10/8/2021 | BK | Takeda to repay $1.7 billion term loan due 2025
|
| 5/9/2018 | BKIG | Moody’s reviews Shire, Baxalta
|
| 5/9/2018 | BKIG | S&P reviews Shire, Takeda
|
| 3/20/2018 | BKIG | Moody’s revises Shire to positive
|
| 12/2/2016 | BK | Shire extends $2.1 billion revolver by one year to December 2021
|
| 9/16/2016 | BKIG | Moody’s rates Shire notes Baa3
|
| 9/16/2016 | BKIG | S&P applies BBB- to Shire notes
|
| 6/3/2016 | BK | Shire draws $12.39 billion of bridge loan to finance Baxalta purchase
|
| 6/3/2016 | BK | Baxalta terminates five-year credit facility upon merging with Shire
|
| 1/28/2016 | BKIG | Moody’s assigns Baa3 to Shire
|
| 1/11/2016 | BKIG | Shire gets $18 billion bridge facility for combination with Baxalta
|
| 11/30/2015 | BK | Shire extends $2.1 billion revolving credit facilities to Dec. 12, 2020
|
| 11/2/2015 | BK | Shire secures $5.6 billion term loan facility for Dyax acquisition
|
| 1/12/2015 | BKBWHY | Shire arranges $850 million short-term bank facility with Citibank to fund NPS Pharma acquisition
|
| 12/17/2014 | BK | Shire enters into $2.1 million five-year revolving credit facility
|
| 7/18/2014 | BKIG | AbbVie secures £13.5 billion bridge facility to fund merger with Shire
|
| 4/11/2014 | BK | Shire reduces term loan to $350 million from $550 million
|
| 2/21/2014 | BK | Shire cancels $350 million of term loan with no convertibles to redeem
|
| 12/16/2013 | BK | Shire, Morgan Stanley agree to cancel $850 million of $1.75 billion term
|
| 11/12/2013 | BK | Shire enters into $2.6 billion facilities agreement via Morgan Stanley
|
| 7/25/2007 | BK | Shire amends loan, increasing revolver size, revising covenants
|
| 5/2/2007 | BK | Shire to repay some bank debt with convertibles proceeds
|
